Log In Sign up
The largest database of trusted experimental protocols

Anti il 6 mab

Manufactured by BioLegend
Visit Supplier

Anti-IL-6 mAb is a monoclonal antibody that binds to the cytokine interleukin-6 (IL-6). It can be used for research purposes to study the biological functions of IL-6.

Automatically generated - may contain errors

Lab products found in correlation

P38 inhibitor 4, by Merck Group (2 mentions) Anti il 4 11b11, by BioLegend (2 mentions) Recombinant tgf β1, by R&D Systems (2 mentions) Mp5 20f3, by BioLegend (2 mentions) Anti cd3, by BioLegend (2 mentions) Pd98059, by Merck Group (2 mentions) Anti cd28, by BioLegend (2 mentions) Anti cd8 mab, by BioLegend (1 mentions) Brefeldin a solution, by BioLegend (1 mentions) Cytofix cytoperm kit, by BD (1 mentions) Monensin, by BioLegend (1 mentions)

3 protocols using anti il 6 mab

1

Induced iTreg Cell Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sorted naive CD4+CD62L+Foxp3EGFP− T cells (1 × 106/ml) were cultured with plate-bound anti-CD28 (5 μg/ml, Biolegend), anti-CD3 (5 μg/ml, Biolegend), recombinant TGF β1 (5 ng/ml, R&D Systems), with or without murine recombinant IL-4 (10 ng/ml) (Perpotech), anti-IL-4 (11B11, 10 μg/ml) (Biolegend) or anti-IL-6 mAb (MP5-20F3, 10 μg/ml) (Biolegend), mitogen activated protein kinase kinase (MEK) inhibitor PD98059 (50 μM, Sigma-Aldrich) or P38 inhibitor IV (10 μM, Sigma-Aldrich). After 4 days, the induced iTreg cells were analyzed by flow cytometry for Foxp3 expression and intracellular cytokines production and/or re-sorted on the basis of EGFP fluorescence.
Massoud A.H., Charbonnier L.M., Lopez D., Pellegrini M., Phipatanakul W, & Chatila T.A. (2016). An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nature medicine, 22(9), 1013-1022.
+ Open protocol
+ Expand
2

Induced iTreg Cell Differentiation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Sorted naive CD4+CD62L+Foxp3EGFP− T cells (1 × 106/ml) were cultured with plate-bound anti-CD28 (5 μg/ml, Biolegend), anti-CD3 (5 μg/ml, Biolegend), recombinant TGF β1 (5 ng/ml, R&D Systems), with or without murine recombinant IL-4 (10 ng/ml) (Perpotech), anti-IL-4 (11B11, 10 μg/ml) (Biolegend) or anti-IL-6 mAb (MP5-20F3, 10 μg/ml) (Biolegend), mitogen activated protein kinase kinase (MEK) inhibitor PD98059 (50 μM, Sigma-Aldrich) or P38 inhibitor IV (10 μM, Sigma-Aldrich). After 4 days, the induced iTreg cells were analyzed by flow cytometry for Foxp3 expression and intracellular cytokines production and/or re-sorted on the basis of EGFP fluorescence.
Massoud A.H., Charbonnier L.M., Lopez D., Pellegrini M., Phipatanakul W, & Chatila T.A. (2016). An asthma-associated IL4R variant exacerbates airway inflammation by promoting conversion of regulatory T cells to TH17-like cells. Nature medicine, 22(9), 1013-1022.
+ Open protocol
+ Expand
3

Isolation and Cytokine Profiling of MedLNs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Following the isolation of MedLNs, single cell suspensions were resuspended with 100ug/mL of LPS (Sigma Aldrich Cat. L2630-100MG) in BLAST medium (RPMI-1640 medium with 10% FCS, b-mercaptoethanol (50uM), L-glutamine, Sodium Pyruvate (2 mM) and PSA (2 mM)) and incubated for 3 hours at 37°C. All cells were treated for 1.5 hours at 37°C with Brefeldin A solution (1:1,000, Biolegend, Cat. 420601) and Monensin (1:1000, Biolegend, Cat. 420701). Cells were labeled with the following mAb mixture anti-CD45 mAb (Biolegend, Cat. 103108, clone 30-F11), anti-CD11c mAb (Biolegend, Cat. 117322, clone), anti-CD103 mAb (Biolegend, Cat. 121433, clone 2E7), anti-CD11b mAb (Biolegend, Cat. 101228, clone M1/70), anti-CD8 mAb (Biolegend, Cat. 100712, clone 53-6.7), fixed, permeabilized, and subjected to intracellular IL-6 staining with the anti-IL-6 mAb (Biolegend, Cat. 504504, clone MP5-20F3) using the Cytofix/Cytoperm kit (BD Biosciences, Cat. BD 554714).
Kozlovski S., Regev O., Sapoznikov A., Kizner M., Achdout H., Petrovich-Kopitman E., Elkahal J., Addadi Y., Silva Castanheira F.V., Feigelson S.W., Kubes P., Erez N., Garbi N, & Alon R. (2023). ICAMs are dispensable for influenza clearance and anti-viral humoral and cellular immunity. Frontiers in Immunology, 13, 1041552.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!